TipRanks
Advertisement
Advertisement
GRIN Therapeutics Highlights Clinical Program Progress at European Epilepsy Congress
PremiumPrivate CompaniesGRIN Therapeutics Highlights Clinical Program Progress at European Epilepsy Congress
1M ago
GRIN Therapeutics Highlights FCDII Clinical Focus and Diagnostic Collaboration
Premium
Private Companies
GRIN Therapeutics Highlights FCDII Clinical Focus and Diagnostic Collaboration
2M ago
GRIN Therapeutics Strengthens Executive Team to Support Neuroscience Clinical Programs
Premium
Private Companies
GRIN Therapeutics Strengthens Executive Team to Support Neuroscience Clinical Programs
2M ago
GRIN Therapeutics Highlights Role of Genetic Testing in GRIN-Related Disorders
PremiumPrivate CompaniesGRIN Therapeutics Highlights Role of Genetic Testing in GRIN-Related Disorders
4M ago
Patient Advocacy Focus Highlighted Around Rare Neurodevelopmental Disorders
Premium
Private Companies
Patient Advocacy Focus Highlighted Around Rare Neurodevelopmental Disorders
4M ago
GRIN Therapeutics Inc – Weekly Recap
Premium
Private Companies
GRIN Therapeutics Inc – Weekly Recap
4M ago
GRIN Therapeutics Highlights Phase 3 Radiprodil Study at Key Epilepsy Meetings in Japan
PremiumPrivate CompaniesGRIN Therapeutics Highlights Phase 3 Radiprodil Study at Key Epilepsy Meetings in Japan
4M ago
GRIN Therapeutics Inc – Weekly Recap
Premium
Private Companies
GRIN Therapeutics Inc – Weekly Recap
5M ago
GRIN Therapeutics Highlights Progress in Phase 3 GRIN-NDD Program and Advocacy-Driven R&D Strategy
Premium
Private Companies
GRIN Therapeutics Highlights Progress in Phase 3 GRIN-NDD Program and Advocacy-Driven R&D Strategy
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―